Fierce Pharma
NOVEMBER 9, 2023
Thanks to a Takeda approval Thursday, patients now have a drug to tackle a rare inherited blood clotting disorder. | The FDA has given a green light to Takeda’s Adzynma, the first recombinant protein product as a preventative or on demand enzyme replacement therapy in adults and kids with congenital thrombotic thrombocytopenic purpura.
Salesforce
NOVEMBER 9, 2023
All marketers are under pressure to reduce costs and drive revenue, but healthcare marketers have the extra pressure of dealing with life or death. How do they balance those business demands while also keeping patients’ and members’ well-being as their top priority? It’s a tough job, but new technologies and healthcare marketing strategies are paving the way for stronger communications that benefit both the company and the people who need care.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
NOVEMBER 9, 2023
AstraZeneca licensed an oral GLP-1 agonist from China's Eccogene. Takeda won FDA approval for the Hutchmed-developed colorectal cancer drug Fruzaqla. | AstraZeneca licensed an oral GLP-1 agonist from China's Eccogene. Takeda won FDA approval for Hutchmed-developed colorectal cancer drug Fruzaqla. BioNTech bought a PD-L1xVEGF bispecific antibody from Chinese biotech Biotheus.
European Pharmaceutical Review
NOVEMBER 9, 2023
Following her presentation on age-related disease at BioFuture 2023, Executive Vice President of Drug Development for MyMD Pharmaceuticals ® , Jenna Brager, shares with EPR why the company’s next-generation tumour necrosis factor (TNF)-alpha inhibitor has potential in inflammatory and autoimmune disorders. In July 2023, MyMD Pharmaceuticals released results from its Phase II study in sarcopenia evaluating potential of MYMD-1 ® , its first-in-class oral TNF-α inhibitor.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Fierce Pharma
NOVEMBER 9, 2023
AstraZeneca chases another liver cancer nod for Imfinzi with early phase 3 win, scraps Imfinzi-Lynparza combo study in lung cancer zbecker Thu, 11/09/2023 - 11:02
European Pharmaceutical Review
NOVEMBER 9, 2023
Sandoz and Teva have become the first organisations to qualify for the new global Minimized Risk of Antimicrobial Resistance (AMR) certification. This programme was developed by the British Standards Institute (BSI) to verify companies that are taking the necessary steps in ensuring responsible antibiotic manufacturing in the global supply chain, helping to lower the spread of AMR.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
PM360
NOVEMBER 9, 2023
Award-winning health and wellness advertising agency AbelsonTaylor Group received the inaugural ACE Aspire Award for its employee Psychological Safety Initiative from the Healthcare Businesswomen’s Association (HBA). The Award was presented yesterday at the HBA Annual Conference in Chicago. The HBA’s ACE (Advancement. Commitment. Engagement.) Awards recognize companies committed to ensuring that gender diversity and leadership opportunities for women are part of their organizational DNA.
Fierce Pharma
NOVEMBER 9, 2023
Takeda scores FDA green light for colorectal cancer drug Fruzaqla, 10 months after acquiring its rights in $1.
MedCity News
NOVEMBER 9, 2023
AstraZeneca gains global rights to an oral GLP-1 agonist on track to reach Phase 2 testing in 2024. Under China-based Eccogene, the small molecule’s Phase 1 data show reductions in glucose and body weight.
Eversana Intouch
NOVEMBER 9, 2023
Back in 2003, drugs from large pharma companies made up 36% of the late-stage R&D pipeline. By 2018, that share had fallen by about half. Meanwhile, the number of companies launching their first drug during the decade preceding 2018 more than tripled. These data are astonishing, given the perception that Big Pharma is the main driver of biopharma innovation.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
MedCity News
NOVEMBER 9, 2023
The Heali app, which launched Thursday, offers personalized nutrition plans for more than 200 chronic conditions, including diabetes, allergies, autoimmune issues and gastrointestinal issues. Users can also access nutrition studies that explain the benefits of certain foods, as well as recipes that fit their diet.
PharmaVoice
NOVEMBER 9, 2023
A gene editing therapy developed by Vertex Pharmaceuticals and CRISPR Therapeutics can mute sickle cell disease’s most damaging symptoms. Yet treatment may not be as simple as its dramatic benefit makes it seem.
European Pharmaceutical Review
NOVEMBER 9, 2023
Daiichi Sankyo’s VANFLYTA ® (quizartinib) is the first FLT3 inhibitor to be approved in the EU for newly diagnosed FLT3 -ITD positive acute myeloid leukaemia (AML). The European Commission (EC) has authorised the anti-cancer treatment in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by VANFLYTA single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia that is FLT3 -ITD positiv
MedCity News
NOVEMBER 9, 2023
About 85,000 Kaiser Permamente workers voted to ratify a new contract, putting to end what was the largest strike in the history of the healthcare industry. The new contract includes terms for higher wages, more employee education, increased hiring and retention efforts, and greater involvement of frontline workers in the health system’s staffing decisions.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
European Pharmaceutical Review
NOVEMBER 9, 2023
Issue 5 of European Pharmaceutical Review features articles on manufacturing, development and quality control of biopharmaceuticals from antibodies to mRNA and cell and gene therapies. In this issue, Peter Stenico, Biosimilar Global Platform Head at Sandoz, highlights how emerging technology platforms such as nanobodies, ADCs and cell and gene therapies are “on course to revolutionise medicine,” with significant growth anticipated over the next decade.
MedCity News
NOVEMBER 9, 2023
In total, there are 3,959 Medicare Advantage plans being offered for individual enrollment in 2024, a 1% decrease from 2023, according to a new report from KFF.
Pharmaceutical Technology
NOVEMBER 9, 2023
GlobalData analyst Jemima Walker discusses key topics around cloud computing for the pharmaceutical industry.
MedCity News
NOVEMBER 9, 2023
Brian Gragnolati, CEO of Atlantic Health System, said that “there’s a war going on between providers and payers right now.” In his view, payers “are doing everything they can” not to pay providers for the care they deliver. He said insurers have greatly increased their rate of denials and are extremely reluctant to take on risk in value-based contracts.
PharmaTimes
NOVEMBER 9, 2023
The WID-qEC test successfully identified 91% of womb cancer cases - News - PharmaTimes
MedCity News
NOVEMBER 9, 2023
Notwithstanding the end of PHEs and corresponding loss in many waivers and policies that allowed for increased telehealth adoption during the pandemic, the recent actions of state governments and private payers indicate that interest in telehealth remains strong.
PharmExec
NOVEMBER 9, 2023
Solomon discusses new ways that researchers are fighting against bacterial resistance to medications.
MedCity News
NOVEMBER 9, 2023
Putting all the AI pieces into place effectively requires clarity of what organizations want to accomplish – and for much of healthcare, the Quadruple Aim remains at the very top. Although how to get there will look different, clarity on principles and values that will guide the development of what comes next is paramount to setting us up for years to come.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
PharmExec
NOVEMBER 9, 2023
A look into the potential effect of psychedelic drugs on various illnesses, such as mental health conditions.
PharmaTimes
NOVEMBER 9, 2023
The campaign was first launched to coincide with the 75th anniversary of the NHS - News - PharmaTimes
PharmExec
NOVEMBER 9, 2023
Healthy Food Rx provides home-delivered medical prescriptions of healthy food to help address diabetes.
pharmaphorum
NOVEMBER 9, 2023
Takeda bags FDA okay for Fruzaqla in colorectal cancer Phil.
Penrod
NOVEMBER 9, 2023
The patient intake experience is a patient’s first impression of your clinic, hospital, or practice. Certainly, many providers have lackluster intake processes…but you don’t have to. By approaching the intake experience as a competitive advantage, you will attract more patients, decrease patient leakage, and drive more revenue. Let’s explore how to make your intake process a competitive advantage.
Happy Living Medical Sales
NOVEMBER 9, 2023
Medical mobility scooters provide enhanced mobility for those with physical mobility issues. These devices can improve the quality of life and safety of people who can't get around as well as they used to. According to a report from the ClinMed International Library, it's estimated that 1.7 million people in the U.S. have mobility scooters or wheelchairs.
Pharmaceutical Technology
NOVEMBER 9, 2023
Every year, the patient recruitment landscape is getting larger and more multi-faceted. The good news is that sponsors now have a wide range of options at their fingertips; the challenge is that it’s becoming harder to oversee the flow of patients and understand what is and isn’t working – and therefore hard to make meaningful decisions that improve the trajectory of recruitment for your trial.
PharmExec
NOVEMBER 9, 2023
Fruquintinib (Fruzaqla) is the first novel chemotherapy-free treatment option approved for metastatic colorectal cancer in more than a decade.
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Expert insights. Personalized for you.
264 
Let's personalize your content